@article{3076802,
    title = "Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus",
    author = "Buske, C. and Dreyling, M. and Alvarez-Larrán, A. and Apperley, J. and Arcaini, L. and Besson, C. and Bullinger, L. and Corradini, P. and Giovanni Della Porta, M. and Dimopoulos, M. and D'Sa, S. and Eich, H.T. and Foà, R. and Ghia, P. and da Silva, M.G. and Gribben, J. and Hajek, R. and Harrison, C. and Heuser, M. and Kiesewetter, B. and Kiladjian, J.J. and Kröger, N. and Moreau, P. and Passweg, J.R. and Peyvandi, F. and Rea, D. and Ribera, J.-M. and Robak, T. and San-Miguel, J.F. and Santini, V. and Sanz, G. and Sonneveld, P. and von Lilienfeld-Toal, M. and Wendtner, C. and Pentheroudakis, G. and Passamonti, F.",
    journal = "ESMO open",
    year = "2022",
    volume = "7",
    number = "2",
    publisher = "Elsevier B.V.",
    doi = "10.1016/j.esmoop.2022.100403",
    abstract = "Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic. © 2022 The Authors"
}